Chemocentryx Stock News

ChemoCentryx Inc. (NASDAQ:CCXI) traded at $36.28 at close of the session on Tuesday, 11/30/21, made a downward move of -1.68% on its previous days price. Looking at the stock we see that its previous close was $36.90 and the beta (5Y monthly) reads 1.44 with the days price range being $34.0058 $37.38. In terms ChemoCentryx Inc. (NASDAQ: CCXI) Drops -1.68%, Turning Investors Away Read More »

ChemoCentryx, Inc. (CCXI) with the stream of 1.71% also noticed, India Evolving Systems, Inc. (EVOL) encountered a rapid change of 0.00% in the last hour of Mondays trading session. ChemoCentryx, The post Alarming Stock: ChemoCentryx, Inc. (NASDAQ:CCXI), Evolving Systems, Inc. (NASDAQ:EVOL) appeared first on Stocks Equity .

Metropolitan Life Insurance Co NY raised its position in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) by 107,064.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,003 shares of the biopharmaceutical companys stock after purchasing an additional 14,989 shares during the period. Metropolitan Life Insurance []

Brokerages predict that ChemoCentryx, Inc. (NASDAQ:CCXI) will report earnings per share (EPS) of ($0.35) for the current quarter, according to Zacks. Six analysts have issued estimates for ChemoCentryxs earnings. The lowest EPS estimate is ($0.60) and the highest is $0.05. ChemoCentryx posted earnings per share of ($0.43) in the same quarter last year, which suggests []

ChemoCentryx Inc. (NASDAQ:CCXI)s traded shares stood at 0.54 million during the latest session, with the companys beta value hitting 1.80. At the last check today, the stocks price was $39.56, to imply an increase of 0.23% or $0.09 in intraday trading. The CCXI shares 52-week high remains $70.29, putting it -77.68% down since that peak ChemoCentryx Inc. (NASDAQ: CCXI) Has Succeeded In Gaining Momentum In 2021, The Stock Is Down -36.26% YTD Read More »

Shares of ChemoCentryx, Inc. (NASDAQ:CCXI) have received a consensus recommendation of Buy from the eight ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average []

ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.

ChemoCentryx (CCXI) posts narrower-than-expected loss for third-quarter 2021. The company's revenues for the quarter also beat estimates.

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two u

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2021 Results - Earnings Call Transcript

ChemoCentryx (CCXI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close

ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.